In GBM samples, enrichment of both PD1+ CD4+ and PD1+ TIM3+ CD4+ T cells suggest combined blockade of multiple checkpoints can be a requirement to tackle aggressive cancers like GBM (192). This evidence concerns the gene CD4 and cancer.